Cambium Bio Limited has released a press release.
Restructuring results in 50% reduction in operating costs
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Cambium Bio
- Updated Investor Presentation
- Offer Booklet
- Investor Presentation
- Successful Private Placement
- Positive results for Progenza in treating neuropathic pain
Later from Cambium Bio
- Appendix 4E
- Regeneus receives A$1.5 million in R&D Tax Incentives
- Japanese Biotech Fund takes up all Rights Issue Shortfall
- Chairmans Address to Shareholders
- CEO Presentation to 2019 Annual General Meeting
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio